12/01/2011

Colour is not a black and white issue


Scientists at the University of Hull have found that some people have the ability to hallucinate colours at will -- even without the help of hypnosis. 

Brain activity [Credit: University of Hull]
The study, published this week in the journal Consciousness and Cognition, was carried out in the Department of Psychology at the University of Hull. It focused on a group of people that had shown themselves to be 'highly suggestible' in hypnosis. 

The subjects were asked to look at a series of monochrome patterns and to see colour in them. They were tested under hypnosis and without hypnosis and both times reported that they were able to see colours. 

Individuals' reactions to the patterns were also captured using an MRI scanner, which enabled the researchers to monitor differences in brain activity between the suggestible and non-suggestible subjects. The results of the research, showed significant changes in brain activity in areas of the brain responsible for visual perception among the suggestible subjects only. 

Professor Giuliana Mazzoni, lead researcher on the project says: "These are very talented people. They can change their perception and experience of the world in ways that the rest of us cannot." 

The ability to change experience at will can be very useful. Research has shown that hypnotic suggestions can be used to block pain and increase the effectiveness of psychotherapy. 

It has always been assumed that hypnosis was needed for these effects to occur, but the new study suggests that this is not true. Although hypnosis does seem to heighten the subjects' ability to see colour, the suggestible subjects were also able to see colours and change their brain activity even without the help of hypnosis. 

The MRI scans also showed clearly that although it was not necessary for the subjects to be under hypnosis to be able to perceive colours in the tests, it was evident that hypnosis increased the ability of the subjects to experience these effects. 

Dr William McGeown, who also contributed to the study, says: "Many people are afraid of hypnosis, although it appears to be very effective in helping with certain medical interventions, particularly pain control. The work we have been doing shows that certain people may benefit from suggestion without the need for hypnosis." 

The study, which was partially funded by the BBC, used a control group formed of less suggestible people, or people less likely to respond to hypnosis. It was found that this group of people were not able to hallucinate colour and, again, these reported results were supported by MRI scans. 

Source: University of Hull [November 30, 2011]

Biologists deliver neutralizing antibodies that protect against HIV infection... in mice


Over the past year, researchers at the California Institute of Technology, and around the world, have been studying a group of potent antibodies that have the ability to neutralize HIV in the lab; their hope is that they may learn how to create a vaccine that makes antibodies with similar properties. Now, biologists at Caltech led by Nobel Laureate David Baltimore, president emeritus and Robert Andrews Millikan Professor of Biology, have taken one step closer to that goal: they have developed a way to deliver these antibodies to mice and, in so doing, have effectively protected them from HIV infection. 

An illustration shows the crystal structure of the adeno-associated virus used to deliver broadly neutralizing antibodies as Vectored ImmunoProphylaxis against HIV [Credit: Alejandro Balazs / California Institute of Technology]
This new approach to HIV prevention -- called Vectored ImmunoProphylaxis, or VIP -- is outlined in the November 30 advance online publication of the journal Nature. 

Traditional efforts to develop a vaccine against HIV have been centered on designing substances that provoke an effective immune response -- either in the form of antibodies to block infection or T cells that attack infected cells. With VIP, protective antibodies are being provided up front. 

"VIP has a similar effect to a vaccine, but without ever calling on the immune system to do any of the work," says Alejandro Balazs, lead author of the study and a postdoctoral scholar in Baltimore's lab. "Normally, you put an antigen or killed bacteria or something into the body, and the immune system figures out how to make an antibody against it. We've taken that whole part out of the equation." 

Because mice are not sensitive to HIV, the researchers used specialized mice carrying human immune cells that are able to grow HIV. They utilized an adeno-associated virus (AAV) -- a small, harmless virus that has been useful in gene-therapy trials -- as a carrier to deliver genes that are able to specify antibody production. The AAV was injected into the leg muscle of mice, and the muscle cells then put broadly neutralizing antibodies into the animals' circulatory systems. After just a single AAV injection, the mice produced high concentrations of these antibodies for the rest of their lives, as shown by intermittent sampling of their blood. Remarkably, these antibodies protected the mice from infection when the researchers exposed them to HIV intravenously.  

The team points out that the leap from mice to humans is large -- the fact that the approach works in mice does not necessarily mean it will be successful in humans. Still, the researchers believe that the large amounts of antibodies that the mice were able to produce -- coupled with the finding that a relatively small amount of antibody has proved protective in the mice -- may translate into human protection against HIV infection. 

"We're not promising that we've actually solved the human problem," says Baltimore. "But the evidence for prevention in these mice is very clear." 

The paper also notes that in the mouse model, VIP worked even in the face of increased exposure to HIV. To test the efficacy of the antibody, the researchers started with a virus dose of one nanogram, which was enough to infect the majority of the mice who received it. When they saw that the mice given VIP could withstand that dose, they continued to bump it up until they were challenging them with 125 nanograms of virus. 

"We expected that at some dose, the antibodies would fail to protect the mice, but it never did -- even when we gave mice 100 times more HIV than would be needed to infect 7 out of 8 mice," says Balazs. "All of the exposures in this work were significantly larger than a human being would be likely to encounter." 

He points out that this outcome likely had more to do with the properties of the antibody that was tested than the method, but adds that VIP is what enabled the large amount of this powerful antibody to circulate through the mice and fight the virus. Furthermore, VIP is a platform technique, meaning that as more potent neutralizing antibodies are isolated or developed for HIV or other infectious organisms, they can also be delivered using this method. 

"If humans are like mice, then we have devised a way to protect against the transmission of HIV from person to person," says Baltimore. "But that is a huge if, and so the next step is to try to find out whether humans behave like mice." 

He says the team is currently in the process of developing a plan to test their method in human clinical trials. The initial tests will ask whether the AAV vector can program the muscle of humans to make levels of antibody that would be expected to be protective against HIV. 

"In typical vaccine studies, those inoculated usually mount an immune response -- you just don't know if it's going to work to fight the virus," explains Balazs. "In this case, because we already know that the antibodies work, my opinion is that if we can induce production of sufficient antibody in people, then the odds that VIP will be successful are actually pretty high." 

Source: California Institute of Technology [November 30, 2011]

Researchers find possible breakthrough to relieve pain following spinal cord injury


A collaborative research group – led by researchers at Cleveland Clinic – published findings that indicate a one-time injection immediately after spinal cord injury can limit pain for an extended period of time. 


Fibronectin – a protein that exists naturally in humans – supports the survival, growth and communication of neurons in the brain and spinal cord. The researchers discovered, through testing in an animal model, that an injection of fibronectin into the spinal cord activates specific signaling pathways and results in pain-curbing effects. 

"We are very pleased with the results from the fibronectin injection," said Ching-Yi Lin, Ph.D., a researcher in the Department of Neurosciences in Cleveland Clinic's Lerner Research Institute. "Perhaps this will signal a change in pain management after spinal cord injury." 

Previous research has shown that spinal cord injury increases the permeability of the blood-spinal cord barrier, causing chronic pain due to exposure of the spinal cord to inflammatory cells. Pain is a particularly important problem after spinal cord injury since the type of pain that ensues after a spinal cord injury is considered even more debilitating than the paralysis itself. 

The findings were published in the December issue of the Journal of Neurotrauma and were presented at the annual meeting of Society of Neuroscience. This is a collaborative project between Lin and Yu-Shang Lee, Ph.D., both of the Department of Neurosciences in Cleveland Clinic's Lerner Research Institute; Vernon Lin, M.D., Ph.D., Department of Physical Medicine and Rehabilitation, Cleveland Clinic; and Jerry Silver, Ph.D., Department of Neurosciences, Case Western Reserve University. 

While the exact mechanisms underlying the possible fibronectin connection to the relief of chronic pain are not clear yet, results show that fibronectin not only maintained the integrity of the blood-spinal cord barrier but also suppressed the inflammatory response significantly over an eight-month period. Researchers found that fibronectin reversed spinal cord injury-induced decreases in serotonin, a neurotransmitter that plays an important role in pain perception. 

The next stage of the study is to test the delayed fibronectin treatment on the inhibition of chronic pain after spinal cord injury, which is more clinically relevant. There is an indication that this treatment also works at later time points.  

Source: Cleveland Clinic [November 30, 2011]

Heart attack risk differs between men and women


Findings on coronary CT angiography (CTA), a noninvasive test to assess the coronary arteries for blockages, show different risk scenarios for men and women, according to a study presented today at the Radiological Society of North America (RSNA). 


Coronary artery disease (CAD) is a narrowing of the blood vessels that supply blood and oxygen to the heart. It is caused by a build-up of fat and other substances that form plaque on vessel walls. According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death for both men and women in the U.S. 

Researchers at the Medical University of South Carolina analyzed the results of coronary CTA on 480 patients, mean age 55, with acute chest pain. Approximately 65 percent of the patients were women, and 35 percent were men. The possibility of acute coronary syndrome was ruled out for each of the patients. 

Using coronary CTA, the researchers were able to determine the number of vessel segments with plaque, the severity of the blockage and the composition of the plaque. 

"The latest CT scanners are able to produce images that allow us to determine whether the plaque is calcified, non-calcified or mixed," said John W. Nance Jr., M.D., currently a radiology resident at Johns Hopkins Hospital in Baltimore, Md. 

By comparing the coronary CTA results with outcome data over a 12.8-month follow-up period, the researchers were able to correlate the extent, severity and type of plaque build-up with the occurrence of major adverse cardiac events, such as a heart attack or coronary bypass surgery. The statistical analysis tested all plaques combined (calcified, non-calcified and mixed) and each individual plaque type separately. 

"We found that the risks for cardiovascular events associated with plaque were significantly different between women and men," Dr. Nance said. 

Within the follow-up period, 70 of the patients experienced major adverse cardiac events, such as death, heart attack, unstable angina or revascularization. In total, 87 major adverse cardiac events occurred among the patients during the follow-up period. 

When the outcome data were correlated with the CTA combined plaque findings, the results indicated that women with a large amount of plaque build-up and extensive atherosclerosis are at significantly greater cardiovascular risk than men. 

Specifically, the risk for major adverse cardiac events was significantly higher in women than in men when extensive plaque of any kind was present or when more than four artery segments were narrowed. 

"This research tells us that extensive coronary plaque is more worrisome in women than the equivalent amount in men," Dr. Nance said. 

However, when analyzing risk factors associated with the presence of individual types of plaque, the risk for major adverse cardiac events was greater in men, compared to women, when their artery segments contained non-calcified plaque. 

Dr. Nance said the new data suggested that the atherosclerotic process, or hardening of the arteries, is not necessarily linear and that more research is needed to better understand the disease. 

"Our research confirms that coronary CTA provides excellent prognostic information that helps identify risk, but there are gender differences that need to be considered," Dr. Nance said.  

Source: Radiological Society of North America [November 30, 2011]

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Facebook Themes